COPD Serum

COPD Serum for Chronic Airway Inflammation Research

Our COPD Serum is sourced from IRB-consented donors with a clinically confirmed diagnosis of chronic obstructive pulmonary disease. Each sample is processed and frozen within 24 hours of collection to preserve cytokines, proteins and metabolites. Serum is acellular, so this product is supplied for soluble-analyte work — multiplex immunoassay, protein quantification, proteomics and metabolomics — in standard or custom aliquot volumes with de-identified clinical annotation.

Why COPD Serum for Airway Inflammation Research

COPD is a chronic inflammatory airway disease, not an autoimmune one. Long-term inhalational injury, most often from tobacco smoke or biomass exposure, drives persistent neutrophil and macrophage recruitment into the airways and lung parenchyma. Oxidative stress amplifies that response, and the resulting imbalance between proteases and their inhibitors degrades elastin and other structural matrix, producing emphysema and irreversible airflow limitation. This local process spills over into the circulation as measurable systemic inflammation.

• Neutrophilic and macrophage inflammation — IL-8/CXCL8 and other neutrophil chemoattractants, along with macrophage-derived mediators, reflect the dominant cellular infiltrate in COPD airways.
• Protease-antiprotease imbalance — neutrophil elastase, matrix metalloproteinases including MMP-9 and MMP-12, and their inhibitors are the mechanistic link between inflammation and matrix destruction.
• Alpha-1 antitrypsin biology — the principal physiological inhibitor of neutrophil elastase is a circulating protein routinely quantified in serum, making serum a standard matrix for antiprotease measurement.
• Oxidative stress markers — products of lipid and protein oxidation and shifts in antioxidant capacity are measurable in the acellular compartment.
• Systemic inflammatory and matrix-turnover mediators — CRP, IL-6 and TNF-α, together with elastin and collagen degradation fragments, characterise the systemic component of the disease.
• Comorbidity and exacerbation biology — cardiovascular, metabolic and cachexia-associated analytes are measurable in serum and are central to understanding why COPD outcomes extend beyond the lung.

Donor Stratification Available

• Airflow limitation severity — donors graded by spirometry-based severity classification where documented
• Clinical phenotype — emphysema-predominant, chronic bronchitis-predominant, and mixed presentations
• Exacerbation history — frequent exacerbators versus stable donors, and samples drawn during exacerbation versus at stable state
• Alpha-1 antitrypsin deficiency status — donors with documented deficiency available as a distinct subgroup
• Smoking status and exposure history — current smokers, former smokers, and never-smokers with occupational or biomass exposure
• Treatment status including inhaled bronchodilator, inhaled corticosteroid, and biologic therapy
• Matched healthy controls available, including smoking-matched controls without airflow limitation

Product Features

• Collected from clinically confirmed COPD donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Verified COPD diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergy and infectious disease history, and comorbidities
• Severity, smoking history and exacerbation context reported per lot where captured
• Additional COPD-specific metadata available on request

Applications

• Neutrophil chemokine and inflammatory mediator quantification
• Matrix metalloproteinase and protease inhibitor measurement
• Alpha-1 antitrypsin quantification and augmentation-therapy research
• Oxidative stress and antioxidant capacity marker profiling
• Extracellular matrix turnover and elastin degradation fragment studies
• Exacerbation biomarker discovery and stable-versus-exacerbation comparison
• Serum proteomic and metabolomic discovery in chronic airway disease
• Systemic comorbidity and cachexia marker research in COPD cohorts

Other COPD Specimen Types

• COPD Plasma
• COPD Bulk Plasma
• COPD PBMC
• COPD Whole Blood
• COPD Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

COPD serum is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human serum page.